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Congenital pseudarthrosis of the tibia (CPT) is a very rare but specifi c condition characterized by anterolateral bowing at birth, and recurrent pathologic fractures of the tibia during early childhood. Fracture usually occurs spontaneously or aft er minor trauma and rarely heals without appropriate surgical intervention, and easily results in pseudarthrosis.
Fibrous hamartoma tissue is regarded as the key pathology of CPT, 1) which occupies the site of pseudarthrosis, and is continuous with abnormally thickened periosteum in the adjacent bone segment.
CPT frequently develops in patients with neurofibromatosis type 1 (NF1). It was reported that association with NF1 was found in 40 to 60 per cent of CPT patients, 2) and CPT develops in 1 to 4 percent of patients with NF1. 3) NF1 is one of the most common autosomal dominant disorders, aff ecting approximately 1 in 3500 births. 4) It is characterized by neurofibromas, cafe-au-lait spots, Lisch nodules and numerous skeletal manifestations, such as macrocephaly, short stature, kyphoscoliosis, sphenoid wing dysplasia, congenital bowing and congenital pseudarthrosis of the tibia.
NF1 is caused by a heterozygous mutation in the Nf1 gene located in chromosome 17q11.2. 5) Th is gene encodes neurofi bromin, which is expressed in a wide range of cells and tissues, 6) including maturing chondrocytes, hypertrophic chondrocytes, osteoblasts, osteocytes, and osteoclasts. 7) It is also expressed in tissues around CPT. 8) Neurofibromin negatively regulates the activity of an intracellular signaling molecule p21 ras (Ras), by functioning as a GTPase activating protein (Ras-GAP). 9, 10) Haploinsufficiency or complete deficiency in Nf1 gene function results in a dose-dependent elevation in Ras activity, which can activate the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3-phosphate kinase (PI-3K) pathway.
11)
The Nf1 gene is classified as a tumor suppressor gene. Heterozygous Nf1 +/-mice experienced tumors and premature death. 12) Chimeric mice containing moderate levels of Nf1 -/-defi cient cells went on to form numerous neurofi bromas, which progressed to malignancy with loss of the p53 tumor suppressor gene. 13) Furthermore, the loss of heterozygosity (LOH) is seen in benign and malignant tumors, including neurofibroma, malignant peripheral nerve sheath tumor (MPNST) and astrocytoma. 14, 15) Previous studies demonstrated that the phenotype of the fi brous hamartoma cells is consistent with the immunophenotype of mesenchymal lineage cells as that of tibial periosteal cells. 16, 17) However, these cells do not undergo osteoblastic differentiation in response to bone morphogenetic protein (BMP), and they are more osteoclastogenic than the tibial periosteal cells. 16) In this study, we investigated further steps of osteoblastic diff erentiation in cells isolated from fi brous hamartoma, in order to delineate the mechanism of impaired osteoblastic diff erentiation of fi brous hamartoma cells.
METHODS

Primary Cell Culture
Th is study was approved by the institutional review board of Seoul National University Hospital. Harvested human tissues were investigated in experiments with informed consent. Fibrous hamartoma tissue was harvested from 11 patients (5 male and 6 female) with an atrophic type of CPT associated with NF1, during surgical procedures for osteosynthesis. Control tissue was obtained from the distal tibial periosteum. A strip of about 2 × 5 mm distal tibial periosteum was harvested during supramalleolar tibial derotation osteotomy from 3 patients without CPT or NF1 (Table 1) . Th ey underwent tissue culture. Fibrous hamartoma or tibial periosteum was enzymatically dissociated to obtain fi broblast-like cells, which were plated on a 100-mm dish, and cultured in DMEM containing 10% FBS and antibiotics at 37 o C in 5% CO 2 . When the second passage cells reached confl uence, they were trypsinized, frozen, and stored in liquid nitrogen until required. Th e cells from fi brous hamartoma were denoted by the labels listed in Table 1 as FH1 through FH11, and cells from the tibial periosteum as PC1 through PC3. A vial of cells from one confl uent dish were thawed and plated on 100-mm dish. When they reached confl uence again, they were re-plated in 1:3 ratio, and rhBMP2 (R&D Systems, Minneapolis, MN, USA) treatment was commenced 48 hours aft er plating. As the amount of tissue harvested from patients was limited, not all tissues were used in the experiments (Table  1) .
Wnt Ligands and Receptors Expression
Total RNA was extracted from plated cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The mRNA expressions of Wnt1, Wnt3a, LRP-5 and β-catenin were assayed by reverse transcription-polymerase chain reaction (Table 2) , to investigate for endogenous Wnt signaling. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control. Regular PCR was performed using AccuPower ® HotStart PCR Premix (Bioneer, Daejeon, Korea) with primers for each gene (Table 2) . Quantitative real-time PCR was performed for Wnt1 and Wnt3a as they showed different band intensity in regular PCR. After reverse transcription using the SuperScript Firststrand Synthesis System for RT-PCR (Invitrogen), realtime PCR was performed in TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) using an ABI Prism 7000 Sequence Detection System (Applied Biosystems). To compare diff erent gene expression levels, threshold cycle (CT) values were compared for relative gene expression analysis. Th e expression levels of target genes were presented as ratio to that of GAPDH. All samples were amplifi ed four times.
Changes in mRNA Expression by rhBMP Treatment
Th e plated cells were grown in osteogenic media (DMEM containing 10% FBS, 100 nM dexamethasone, 10 mM sodium-glycerophosphate, and 0.05 mM ascorbic acid-2-phosphate). Th ey were divided into two groups. Group I was grown solely in osteogenic media. Group II was treated with 100 ng/mL rhBMP2 (R&D Systems) for 2 weeks. Total RNA was extracted following 2 weeks of treatment. Th e mRNA levels of osteoblast markers, such as col1a1, os- (Table 3) . Real-time PCR and quantifi cation method was identical to that described previously. Th e expression level of rhBMP2 treated cell was divided by that of untreated cell to calculate the extent of up-regulation or down-regulation of the expression.
RESULTS
Wnt Ligands and Receptors Expression
Control tissue (PC1) and fi brous hamartoma tissues from five patients (FH1-5) underwent quantitative real-time RT-PCR for Wnt1 and Wnt3a, and qualitative RT-PCR for Lrp-5 and β-catenin. In the fi brous hamartoma from all 5 CPT patients, the mRNA levels of Wnt ligands were lower than that of control tissue. Expression level of these ligands varied from patient to patient. The mRNA level of Wnt1 in the fibrous hamartoma ranged from 3.3% to 34.2% of that of normal control tissue, while Wnt3a mRNA expression level ranged from 0.14% to 13.5%. All tissues showed strong mRNA expression of both Lrp-5 and β-catenin in RT-PCR (Fig. 1) .
Osteoblast Marker Gene Expression Change by BMP Treatment
Th e mRNA level of osteoblast markers, including col1a1, osteocalcin, and ALPL were analyzed in 2 control tissues (PC1, PC2) and 9 fi brous hamartoma tissues (FH1-FH9).
Th e control tissues (periosteal cells) showed up-regulation of mRNA expression of col1a1, osteocalcin and ALPL in response to rhBMP-2 treatment. Col1a1 mRNA level increased by 1.65-or 1.94-fold, osteocalcin by more than 2.0-fold, and ALPL by more than 3.0-fold. However, the response of fi brous hamartoma remained inconsistent. In 7 of 9 FH's, the mRNA expression of col1a1 increased by more than 10% of non-treatment control, while in 2 FH's, it increased by 10% or decreased by 21%, respectively ( Fig.  2A) . Osteocalcin mRNA expression was up-regulated by rhBMP in fewer FH's than col1a1. Only 2 FH's showed up-regulation of osteocalcin gene expression, and 6 FH's showed down-regulation of osteocalcin gene expression by rhBMP2 treatment (Fig. 2B) . ALP gene expression was down-regulated by rhBPM2 treatment in 7 FH's, and that of the remaining 2 FH's remained within 10% of that of untreated control. Th is was in contrast to more than 3-fold up-regulation in the periosteal cells (PC1 and PC2) (Fig.  2C) . (Fig. 3 ) Transcription factors involved in osteoblastic diff erentiation, such as Dlx5, Msx2, Runx2, and Osterix, were analyzed in 10 FH's (FH1-FH8, FH10, FH11) and 2 periosteal cells. Periosteal cells showed responses compatible with osteoblastic differentiation. Dlx5, Runx2, and Osterix mRNA expressions were up-regulated with rhBMP2 treatment by 52%, 59, and 20%, respectively, and that of Msx2 was down-regulated by 48%. In FH's, changes in mRNA expression of these transcription factors were not consistent. Dlx5 expression was up-regulated in all FH's tested. Th e extent of up-regulation was similar to or larger than the two periosteal cells in 9 of 10 FH's tested. FH2 showed mild up-regulation, which was smaller than that of either PC1 or PC3. Msx2 was down-regulated as periosteal cells in 9 of 10 FH's tested. However, only one FH (FH10) showed down-regulation more than the PC's. In 8 of 10 FH's tested, the extent of down-regulation of Msx2 mRNA expression was less than 20% of the untreated cells, while that of PC's were more than 40%. One FH (FH4) even showed up-regulation of Msx2 expression. Runx2 mRNA expression was up-regulated in 8 FH's, and down-regulated in 2 FH's. FH8 showed 8.7-fold up-regulation, which also showed the largest up-regulation of Dlx5 expression. However, FH8 showed down-regulation of osteocalcin and ALPL mRNA expression. Osterix mRNA expression was diverse. Two HF's showed up-regulation larger than PC1, while three showed down-regulation by rhBMP2 treatment.
DISCUSSION
This study was limited by the fact that mRNA expressions of fibrous hamartoma from CPT associated with NF1 were compared to that of periosteal cells from non-NF1 patients. The findings might reflect the difference between Nf1 haploinsufficient cells and wild-type cells, but it does not explain why fi brous hamartoma develops on distal tibia specifi cally in systemically Nf1 haploinsuffi cient individual. In order to address this question, fi brous hamartoma cells should be compared with periosteal cells from normal-looking contralateral distal tibia of the same patient. However, it would be unethical to harvest it only for research purpose. We investigated several aspects of the osteoblastic differentiation process in primary cultured cells from fi brous hamartoma believed to be the main pathologic tissue in CPT associated with NF1. Although the data were not consistent throughout all cases investigated in this study, fibrous hamartoma cells showed deficient expression of the Wnt ligands which are important factors in the regulation of bone mass, postnatal bone formation and fracture healing process. 18) When stimulated by rhBMP2 treatment, most fibrous hamartoma cells up-regulated col1a1 expression. However, only a subset up-regulated osteocalcin expression, and all of them down-regulated ALP expression. These findings were consistent with a published report on a smaller number of cases. 16) Osteoblastogenesis is a complex process of cell differentiation from mesenchymal stem cell through osteoprogenitor and preosteoblast to osteoblast. Wnts and BMPs are the most important signal molecules that regulate this process. In this study, we investigated mRNA expression of the Wnt ligands (Wnt1 and Wnt3a), and their receptors of the canonical pathway (Lrp5 and β-catenin). Wnts are a large family of growth factors involved in a variety of biological processes. Th e canonical pathway of Wnt signal mediated through β-catenin/Lrp5 modulates most aspects of osteoblastic physiology, including proliferation, differentiation, bone matrix formation/mineralization and apoptosis. 19) We showed that the mRNA expression of Wnt1 and Wnt3a, which are known to be involved in osteoblastogenesis, were signifi cantly low in fi brous hamartoma cells, although the receptors' mRNA expression was comparable to control tissue. Th is means that defi ciency of local Wnt ligands may contribute to disturbed osteoblastic diff erentiation in fi brous hamartoma in the pathogenesis of CPT. It appears worthwhile to further investigate Wnt signaling systematically in CPT associated with NF1.
In a previous study, BMP2, BMP4, BMPR1A, BM- PR1B, and BMPR2 were reported to express in fibrous hamartoma of CPT. 16 ) BMP signals induce receptormediated signaling pathways involving Smads, and subsequently transcriptions factors specifi c for osteoblastic differentiation. Runx 2 is the master osteogenic transcription factor, expresses in early skeletal development and persists through subsequent stages of bone formation. 20, 21) Dlx5 is a bone inducing homeodomain transcription factor, expressed in the later stages of osteoblastic diff erentiation, which is considered to be an upstream regulator of Runx2 and Osterix in the BMP-2 signaling pathway. 22) Osterix is a zinc fi nger-containing transcription factor, specifi cally expressed in all developing bones, which is considered to act mainly during the terminal diff erentiation of osteoblasts. 21) Msx2 is a mammalian homologue of the Drosophila muscle segment homeobox gene, which appears to play a negative role in osteoblast diff erentiation, stimulating cell proliferation and suppressing osteogenic diff erentiation. 21) Hence, BMP signaling appears to be transduced via Smads to Dlx5, and then to Runx2 for early diff erentiation, and to Osterix for terminal differentiation and Msx2 antagonizes these pathways. In our control tissue -the periosteal cells -up-regulated Dlx5, Runx2 and Osterix were seen in response to BMP stimulation, whereas Msx2 was downregulated. Hence, we attempted to delineate the response of these transcription factor expressions in fibrous hamartoma cells. It is noteworthy that both Dlx5 and Runx2 responded in a way similar to the periosteal cells in most cases of fi brous hamartoma. On the other hand, Msx2 expression was not suppressed by BMP stimulation as much as in the periosteal cells in most cases of fibrous hamartoma. In addition, Osterix expression was down-regulated in 3 of 5 FH's. Th ese fi ndings suggest that impairment of osteoblastic differentiation in fibrous hamartoma is the terminal step of the differentiation cascade and interference by Msx2 may work in this process. Another aspect of these fi ndings that we need to pay attention is that the behavior of FH's varies from patient to patient.
In conclusion, the fi ndings in this study support the hypothesis that fi brous hamartoma originates from aberrant growth of Nf1 haploinsuffi cient periosteal cells, which failed in terminal osteoblastic diff erentiation, arrested at a certain stage of this process. Th is pathomechanism of CPT should be targeted in the development of novel therapeutic biologic intervention.
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